NCT01745185View on ClinicalTrials.gov

Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 7, 2015

Study Completion Date

August 7, 2016

Conditions
Fabry Disease
Trial Locations (1)

22030

O&O Alpan, Fairfax

All Listed Sponsors
lead

O & O Alpan LLC

OTHER

NCT01745185 - Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta | Biotech Hunter | Biotech Hunter